

Bi-Specific Antibodies Therapy Industry Research Report 2023

<https://marketpublishers.com/r/B2FC3D53FF1EEN.html>

Date: August 2023

Pages: 89

Price: US\$ 2,950.00 (Single User License)

ID: B2FC3D53FF1EEN

Abstracts

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Highlights

The global Bi-Specific Antibodies Therapy market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bi-Specific Antibodies Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche

Amgen

Sanofi

Pfizer

Johnson & Johnson

AstraZeneca

AbbVie

Lindis Biotech

MacroGenics, Inc

Genmab

Alphamab Co. Ltd

Akeso, Inc.

Product Type Insights

Global markets are presented by Bi-Specific Antibodies Therapy type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Bi-Specific Antibodies Therapy are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Bi-Specific Antibodies Therapy segment by Type

Fragment-Based Antibodies

IgG-Based Antibodies

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Bi-Specific Antibodies Therapy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Bi-Specific Antibodies Therapy market.

Bi-Specific Antibodies Therapy Segment by Application

Cancer

Haemophilia

Other Non-Cancer Diseases

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Bi-Specific Antibodies Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Bi-Specific Antibodies Therapy industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market,

the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Bi-Specific Antibodies Therapy companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?

Which end-use segment will expand at the fastest CAGR in the Product Name market?

Which are the emerging players in the Product Name market?

How concentrated is the Product Name market?

Which factors are positively contributing to the Product Name market growth?

Which are the novel product innovations in the Product Name market?

Which product segment will emerge as the most lucrative in the Product Name market?

Which factors are increasing the competition in the Product Name market?

Which are the strategic measures taken by the Product Name industry players?

Which region will witness inactive growth during the forecast period?

What key trends are likely to emerge in the Product Name market in the coming years?

Contents

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Bi-Specific Antibodies Therapy Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2018-2023)

Table 7. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2024-2029)

Table 9. Global Bi-Specific Antibodies Therapy Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2018-2023)

Table 11. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2024-2029)

Table 13. Global Bi-Specific Antibodies Therapy Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Bi-Specific Antibodies Therapy Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Bi-Specific Antibodies Therapy Market Share by Region (2018-2023)

Table 16. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Bi-Specific Antibodies Therapy Market Share by Region (2024-2029)

Table 18. Bi-Specific Antibodies Therapy Market Trends

Table 19. Bi-Specific Antibodies Therapy Market Drivers

Table 20. Bi-Specific Antibodies Therapy Market Challenges

Table 21. Bi-Specific Antibodies Therapy Market Restraints

Table 22. Global Top Bi-Specific Antibodies Therapy Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Bi-Specific Antibodies Therapy Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Bi-Specific Antibodies Therapy Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Bi-Specific Antibodies Therapy, Headquarters and Area Served

Table 26. Global Bi-Specific Antibodies Therapy Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global Bi-Specific Antibodies Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country

(2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Roche Company Detail

Table 46. Roche Business Overview

Table 47. Roche Bi-Specific Antibodies Therapy Product

Table 48. Roche Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 49. Roche Recent Development

Table 50. Amgen Company Detail

Table 51. Amgen Business Overview

Table 52. Amgen Bi-Specific Antibodies Therapy Product

Table 53. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 54. Amgen Recent Development

Table 55. Sanofi Company Detail

Table 56. Sanofi Business Overview

Table 57. Sanofi Bi-Specific Antibodies Therapy Product

Table 58. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 59. Sanofi Recent Development

Table 60. Pfizer Company Detail

Table 61. Pfizer Business Overview

Table 62. Pfizer Bi-Specific Antibodies Therapy Product

Table 63. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 64. Pfizer Recent Development

Table 65. Johnson & Johnson Company Detail

Table 66. Johnson & Johnson Business Overview

Table 67. Johnson & Johnson Bi-Specific Antibodies Therapy Product

Table 68. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 69. Johnson & Johnson Recent Development

Table 70. AstraZeneca Company Detail

Table 71. AstraZeneca Business Overview

Table 72. AstraZeneca Bi-Specific Antibodies Therapy Product

Table 73. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)

Table 74. AstraZeneca Recent Development

- Table 75. AbbVie Company Detail
- Table 76. AbbVie Business Overview
- Table 77. AbbVie Bi-Specific Antibodies Therapy Product
- Table 78. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 79. AbbVie Recent Development
- Table 80. Lindis Biotech Company Detail
- Table 81. Lindis Biotech Business Overview
- Table 82. Lindis Biotech Bi-Specific Antibodies Therapy Product
- Table 83. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 84. Lindis Biotech Recent Development
- Table 85. MacroGenics, Inc Company Detail
- Table 86. MacroGenics, Inc Business Overview
- Table 87. MacroGenics, Inc Bi-Specific Antibodies Therapy Product
- Table 88. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 89. MacroGenics, Inc Recent Development
- Table 90. Genmab Company Detail
- Table 91. Genmab Business Overview
- Table 92. Genmab Bi-Specific Antibodies Therapy Product
- Table 93. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 94. Genmab Recent Development
- Table 95. Alhamab Co. Ltd Company Detail
- Table 96. Alhamab Co. Ltd Business Overview
- Table 97. Alhamab Co. Ltd Bi-Specific Antibodies TherapyProduct
- Table 98. Alhamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 99. Alhamab Co. Ltd Recent Development
- Table 100. Akeso, Inc. Company Detail
- Table 101. Akeso, Inc. Business Overview
- Table 102. Akeso, Inc. Bi-Specific Antibodies TherapyProduct
- Table 103. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US\$ Million)
- Table 104. Akeso, Inc. Recent Development
- Table 105. Roche Company Information
- Table 106. Roche Business Overview
- Table 107. Roche Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies

Therapy Business (2018-2023) & (US\$ Million)

Table 108. Roche Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 109. Roche Recent Development

Table 110. Amgen Company Information

Table 111. Amgen Business Overview

Table 112. Amgen Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 113. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 114. Amgen Recent Development

Table 115. Sanofi Company Information

Table 116. Sanofi Business Overview

Table 117. Sanofi Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 118. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 119. Sanofi Recent Development

Table 120. Pfizer Company Information

Table 121. Pfizer Business Overview

Table 122. Pfizer Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 123. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 124. Pfizer Recent Development

Table 125. Johnson & Johnson Company Information

Table 126. Johnson & Johnson Business Overview

Table 127. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 128. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 129. Johnson & Johnson Recent Development

Table 130. AstraZeneca Company Information

Table 131. AstraZeneca Business Overview

Table 132. AstraZeneca Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 133. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio

Table 134. AstraZeneca Recent Development

- Table 135. AbbVie Company Information
- Table 136. AbbVie Business Overview
- Table 137. AbbVie Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)
- Table 138. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio
- Table 139. AbbVie Recent Development
- Table 140. Lindis Biotech Company Information
- Table 141. Lindis Biotech Business Overview
- Table 142. Lindis Biotech Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)
- Table 143. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio
- Table 144. Lindis Biotech Recent Development
- Table 145. MacroGenics, Inc Company Information
- Table 146. MacroGenics, Inc Business Overview
- Table 147. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)
- Table 148. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio
- Table 149. MacroGenics, Inc Recent Development
- Table 150. Genmab Company Information
- Table 151. Genmab Business Overview
- Table 152. Genmab Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)
- Table 153. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio
- Table 154. Genmab Recent Development
- Table 155. Alphamab Co. Ltd Company Information
- Table 156. Alphamab Co. Ltd Business Overview
- Table 157. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)
- Table 158. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million) Portfolio
- Table 159. Alphamab Co. Ltd Recent Development
- Table 160. Akeso, Inc. Company Information
- Table 161. Akeso, Inc. Business Overview
- Table 162. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2018-2023) & (US\$ Million)

Table 163. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business
(2018-2023) & (US\$ Million) Portfolio

Table 164. Akeso, Inc. Recent Development

Table 165. Authors 12. List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Bi-Specific Antibodies Therapy Product Picture

Figure 5. Global Bi-Specific Antibodies Therapy Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global Bi-Specific Antibodies Therapy Market Share by Type: 2022 VS 2029

Figure 7. Fragment-Based Antibodies Product Picture

Figure 8. IgG-Based Antibodies Product Picture

Figure 9. Global Bi-Specific Antibodies Therapy Market Size by Application (2023-2029) & (US\$ Million)

Figure 10. Global Bi-Specific Antibodies Therapy Market Share by Application: 2022 VS 2029

Figure 11. Cancer Product Picture

Figure 12. Haemophilia Product Picture

Figure 13. Other Non-Cancer Diseases Product Picture

Figure 14. Global Bi-Specific Antibodies Therapy Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Bi-Specific Antibodies Therapy Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Bi-Specific Antibodies Therapy Market Share by Region: 2022 VS 2029

Figure 17. Global Bi-Specific Antibodies Therapy Market Share by Players in 2022

Figure 18. Global Bi-Specific Antibodies Therapy Players, Date of Enter into This Industry

Figure 19. Global Top 5 and 10 Bi-Specific Antibodies Therapy Players Market Share by Revenue in 2022

Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 21. North America Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. North America Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)

Figure 23. United States Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Canada Bi-Specific Antibodies Therapy Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 25. Europe Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Europe Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)

Figure 27. Germany Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. France Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. U.K. Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Italy Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Russia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Nordic Countries Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)

Figure 35. China Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Japan Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. South Korea Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Southeast Asia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. India Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Australia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)

Figure 43. Mexico Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Brazil Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2018-2029)

Figure 47. Turkey Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Saudi Arabia Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. UAE Bi-Specific Antibodies Therapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 50. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 51. Amgen Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 52. Sanofi Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 53. Pfizer Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 54. Johnson & Johnson Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 55. AstraZeneca Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 56. AbbVie Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 57. Lindis Biotech Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 58. MacroGenics, Inc Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 59. Genmab Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 60. Alphamab Co. Ltd Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

Figure 61. Akeso, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2018-2023)

I would like to order

Product name: Bi-Specific Antibodies Therapy Industry Research Report 2023

Product link: <https://marketpublishers.com/r/B2FC3D53FF1EEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2FC3D53FF1EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970